CD5L and metabolic dysfunction-associated steatotic liver disease: The differential expression of two acute phase proteins, serum amyloid P-component (APCS) and CD5 antigen-like protein (CD5L), between two overweight groups, suggests their potential as predictive markers for NAFLD in obese patients, as they regulate the innate and adaptive immune systems (15, 32).